On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...